Even when it has metastasized - Radiation to the prostate in metastatic prostate cancer Talking Oncology

Join Joseph Ischia, Amy Teh and Nick James as they discuss radiation to the prostate in metastatic prostate cancer. Dr Amy Teh is the Lead Regional Radiation Oncologist at the ICON Cancer Centre for NSW/ACT, a consultant Radiation Oncologist at the Sydney Adventist Hospital and a Clinical Senior Lecturer at the Sydney Medical School, The University of Sydney. A member of TROG and ANZUP Clinical Trials Group, Dr Teh is lead site-investigator for the RAVES, ENZARAD, DASL-HiCap prostate cancer trials at the Sydney Adventist Hospital and has led the Prostate Brachytherapy Program at the Sydney Adventist Hospital, and also the Radiation Oncology Research Committee Co-Chair for the ICON Cancer Centre. Professor James is Consultant in Clinical Oncology at the Queen Elizabeth Hospital Birmingham and Professor of Clinical Oncology at the University of Birmingham. Professor James is internationally renowned for his work in Urological Cancer, particularly on the ground-breaking STAMPEDE trial, which has been used to evaluate, to date, 10 different therapies for advanced prostate cancer in more than 10,000 men. He is a regular educational speaker at conferences worldwide, recently including the American Society of Clinical Oncology, European Society of Medical Oncology and European Association of Urologists Annual Meetings. Results from STAMPEDE with both first line docetaxel chemotherapy and abiraterone have shown that big survival gains can be made by using existing treatments in novel settings. These findings have been practice changing worldwide.